BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects

Eli Lilly and Company (NYSE:LLY) is one of the top stock picks in Ken Griffin’s portfolio. On August 27, BMO Capital reiterated its ‘Outperform’ rating with a $840 price target for the stock. The positive stance comes on the pharmaceutical giant delivering positive ATTAIN-2 clinical trial results for the weight loss drug orforglipron.

BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects

Pixabay/Public Domain

The ATTAIN-2 study showed peak placebo-adjusted weight loss of 8.3% in obese patients with type 2 diabetes. The positive results have set up orforglipron for a potential US Food and Drug Administration filing by the end of the year.

BMO Capital remains confident that orforglipron has the potential to strengthen Eli Lilly’s prospects in the weight loss market. It thus expects the company’s shares to trade higher as investors’ expectations have been reset following the previous ATTAIN-1 results.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines to improve human health, with a focus on therapeutic areas such as diabetes, oncology, immunology, and neuroscience.

While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: Goldman Sachs Tech Stocks: Top 10 Stocks to Buy Now and 10 Must-Buy Penny Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.